LifeStance Health Group Inc

Sell now into the marginal new‐high resistance area; the Bullish Exhaustion pattern combined with extreme overbought conditions and a Stage 3 distribution context suggest a high probability pullback or reversal, warranting bearish participation.

• ↑26% YoY revenue growth to $435M in Q2, net income rebounded to $24M.
• ↑Raised 2026 revenue guidance to $1.685–1.725B, implying ~20% growth.
• ↓Elevated volatility may cause large stock price swings and deter investors.